Schedule 13G ownership disclosure
THERAVANCE BIOPHARMA INC
Common Stock · CUSIP: G8807B106
Event date: 2025-03-31
- Filing-level shares
- 3,235,696.00
- Percent of class
- 6.5%
- BlackRock, Inc.
Shares: 3,235,696.00 · Class: 6.5%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0002052113-25-002028
- Form type
- SCHEDULE 13G/A
- Filer
- BlackRock, Inc.
- CIK
- CIK 2012383
- Filed
- Apr 30, 2025
- Reporting period
- Mar 31, 2025
- Description
- Schedule 13G beneficial ownership